Jefferies Financial Group Inc. Sells 284,000 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Jefferies Financial Group Inc. lessened its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 90.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,048 shares of the company's stock after selling 284,000 shares during the period. Jefferies Financial Group Inc.'s holdings in 10x Genomics were worth $446,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Signaturefd LLC grew its holdings in shares of 10x Genomics by 424.6% during the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock worth $26,000 after acquiring an additional 1,452 shares during the period. Blue Trust Inc. grew its holdings in shares of 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after acquiring an additional 1,299 shares during the period. Sound Income Strategies LLC grew its holdings in shares of 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after acquiring an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of 10x Genomics during the 4th quarter worth approximately $52,000. Finally, SRS Capital Advisors Inc. grew its holdings in shares of 10x Genomics by 817.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock worth $70,000 after acquiring an additional 4,324 shares during the period. Hedge funds and other institutional investors own 84.68% of the company's stock.

Insider Activity

In related news, CEO Serge Saxonov sold 5,092 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the transaction, the chief executive officer now directly owns 879,482 shares of the company's stock, valued at approximately $9,735,865.74. This trade represents a 0.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the transaction, the insider now directly owns 335,324 shares in the company, valued at approximately $3,712,036.68. This represents a 1.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 9.39% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. reduced their target price on 10x Genomics from $12.00 to $9.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. UBS Group cut their price target on 10x Genomics from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Canaccord Genuity Group cut their price target on 10x Genomics from $18.00 to $15.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Leerink Partnrs downgraded 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 13th. Finally, Leerink Partners downgraded 10x Genomics from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $25.00 to $12.00 in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $15.81.

10x Genomics Trading Down 4.9%

TXG stock traded down $0.46 during midday trading on Monday, hitting $8.93. The company's stock had a trading volume of 4,292,293 shares, compared to its average volume of 2,375,780. The company has a market cap of $1.09 billion, a PE ratio of -5.88 and a beta of 1.94. 10x Genomics, Inc. has a 12 month low of $6.78 and a 12 month high of $25.55. The firm's 50-day moving average is $8.73 and its 200-day moving average is $12.26.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.09. The business had revenue of $154.88 million for the quarter, compared to analysts' expectations of $131.91 million. 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. The firm's quarterly revenue was down 2.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.50) EPS. Analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.